Subscribe to RSS
Synthesis of a Selective Estrogen Receptor β-Modulator
M. A. Huffman*, J. D. Rosen, R. N. Farr, J. E. Lynch
Merck & Co., Inc., Rahway, USA
23 August 2007 (online)
The target molecule (I) is being developed to avoid the adverse side effects of hormone replacement therapy. The key step is an asymmetric phase-transfer-catalyzed alkylation of the indanone D using commercial N-(p-trifluoromethylbenzyl)cinchoninium bromide (E) as catalyst. For a related indanone alkylation, see: A. Bhattacharya et al. Angew. Chem., Int. Ed. Engl. 1986, 25, 476.